The RRM2B (Ribonucleotide Reductase Regulatory TP53 Inducible Subunit M2B) gene encodes a critical enzyme in nucleotide metabolism, specifically the p53-inducible small subunit of ribonucleotide reductase (RNR). This enzyme is essential for deoxyribonucleotide (dNTP) synthesis, mitochondrial DNA (mtDNA) maintenance, and cellular responses to DNA damage. Located on chromosome 8q23.1, RRM2B plays a vital role in both nuclear and mitochondrial genome integrity.
| Property |
Value |
| Gene Symbol |
RRM2B |
| Full Name |
Ribonucleotide Reductase Regulatory TP53 Inducible Subunit M2B |
| Chromosomal Location |
8q23.1 |
| NCBI Gene ID |
50484 |
| OMIM ID |
604712 |
| Ensembl ID |
ENSG00000068912 |
| UniProt ID |
Q7LG56 |
| Encoded Protein |
p53-inducible ribonucleotide reductase subunit M2B |
| Protein Length |
389 amino acids |
| Molecular Weight |
~45 kDa |
¶ Gene Structure and Organization
The RRM2B gene contains multiple exons that encode a protein with distinct functional domains. Unlike its paralog RRM2, RRM2B is induced by p53, making it a key mediator of p53-dependent cell cycle control and DNA damage response.
The protein contains:
- N-terminal domain: Interaction with the large RRM1 subunit
- Active site: Contains iron-sulfur cluster for catalytic activity
- C-terminal region: Regulatory sequences controlling protein stability
¶ Normal Function and Biochemistry
Ribonucleotide reductase (RNR) is the rate-limiting enzyme for dNTP synthesis, catalyzing the reduction of ribonucleotides to their corresponding deoxyribonucleotides. RNR consists of two subunits:
- Large subunit (RRM1): Contains the catalytic site
- Small subunit: Provides the iron-sulfur center and allosteric regulation sites
RRM2B serves as an alternative small subunit to RRM2, with several key differences:
- p53 inducibility: RRM2B expression is directly induced by p53
- Tissue-specific expression: Higher expression in tissues with high mitochondrial demand
- Mitochondrial targeting: Contributes to mtDNA maintenance
The RNR reaction proceeds through a radical-based mechanism:
- Ribonucleoside diphosphate (NDP) binds to the active site
- A thiyl radical, generated from the iron-sulfur cluster, abstracts a hydrogen from the substrate
- The radical intermediate is reduced by conserved cysteines
- Deoxyribonucleoside diphosphate (dNDP) is released
- Nucleoside diphosphate kinase converts dNDP to dNTP
RRM2B-containing RNR has distinct kinetic properties compared to RRM2-containing RNR, particularly in response to changing cellular conditions.
As a p53 target gene, RRM2B links DNA damage sensing to nucleotide metabolism:
- p53 activation by DNA damage → increased RRM2B transcription
- Increased dNTP pools support DNA repair and replication
- Cell cycle arrest maintenance through nucleotide depletion (indirectly)
This pathway ensures sufficient nucleotides for DNA repair while preventing replication of damaged DNA.
RRM2B is expressed in most human tissues, with highest levels in:
- Skeletal muscle: High mitochondrial content and energy demand
- Heart: Continuous oxidative phosphorylation
- Brain: Particularly in neurons with high metabolic demand
- Kidney: High energy requirements for transport
- Liver: Metabolic hub with mitochondrial function
Within the central nervous system, RRM2B shows specific patterns:
- Neurons: High expression, particularly in large projection neurons
- Astrocytes: Moderate expression supporting metabolic functions
- Oligodendrocytes: Important for myelin maintenance
- Developing brain: Higher expression during neurogenesis
¶ Mitochondrial DNA Maintenance
RRM2B is critical for mtDNA replication and maintenance:
- mtDNA replication requires dNTPs synthesized within mitochondria
- RRM2B contributes to the mitochondrial dNTP pool
- Mitochondrial DNA depletion is a hallmark of RRM2B deficiency
- mtDNA copy number regulation depends on RRM2B function
RRM2B deficiency affects mitochondrial morphology and function:
- Fragmented mitochondria: Loss of healthy tubular network
- Reduced mitochondrial mass: Decreased mtDNA copy number
- Impaired respiration: Reduced oxidative phosphorylation
- Increased mitophagy: Clearance of dysfunctional mitochondria
p53 has well-documented effects on mitochondrial function:
- Direct mitochondrial translocation under stress
- Regulation of mitochondrial apoptosis
- Interaction with RRM2B coordinates nuclear and mitochondrial genome maintenance
RRM2B mutations cause a form of mitochondrial DNA depletion syndrome, characterized by:
- Progressive mitochondrial myopathy: Muscle weakness, exercise intolerance
- Encephalomyopathy: Brain involvement with developmental regression
- Early-onset neurodegeneration: Often presenting in infancy or childhood
- Failure to thrive: Growth retardation
- Elevated lactic acid: Metabolic derangement
The spectrum ranges from severe early-onset disease to milder forms with later onset.
Several RRM2B-related conditions have been described:
MTDPS7 (Mitochondrial DNA Depletion Syndrome 7):
- Characterized by early-onset progressive encephalomyopathy
- Features include: seizures, developmental regression, ataxia
- Often fatal in childhood
Mitochondrial Myopathy:
- Predominant muscle involvement
- Exercise intolerance, weakness
- May respond to treatment
The p53-RRM2B connection has implications for cancer:
- TP53 mutations may dysregulate RRM2B
- Altered dNTP pools can affect DNA repair fidelity
- RRM2B expression correlates with tumor prognosis in some cancers
Beyond mtDNA depletion syndromes, RRM2B may contribute to:
Alzheimer's Disease:
- p53 dysregulation is common in AD
- Altered nucleotide metabolism may affect DNA repair
- Mitochondrial dysfunction is a key AD feature
Parkinson's Disease:
- Mitochondrial dysfunction is central to PD pathogenesis
- RRM2B variants may modify risk
- The p53-PINK1 pathway intersects with RRM2B function
Other Conditions:
- Huntington's disease (mitochondrial dysfunction)
- Amyotrophic lateral sclerosis
- Aging-related neurodegeneration
Pathogenic RRM2B variants include:
- Missense mutations: Often affect the iron-sulfur center
- Nonsense mutations: Create premature stop codons
- Splice-site mutations: Cause exon skipping
- Frameshift mutations: Alter protein reading frame
- Biallelic null mutations: Severe early-onset disease
- Missense mutations: Variable severity, sometimes responsive to treatment
- Compound heterozygosity: Intermediate phenotypes
Autosomal recessive: Both alleles must be affected for disease manifestation. Carriers are typically asymptomatic.
- Molecular testing: RRM2B sequencing
- mtDNA copy number: Reduced in patient tissues
- Enzyme activity: RNR activity in patient cells
- Biochemical testing: Elevated lactate, reduced respiratory chain function
Potential therapeutic strategies include:
- dNTP supplementation: Exogenous nucleotide administration
- Ribonucleotide reductase modulators: Enhance residual activity
- Substrate-level approaches: Increase precursor availability
Emerging approaches:
- AAV-mediated RRM2B delivery: Viral vector gene replacement
- CRISPR-based approaches: Precise gene correction
- mRNA delivery: Transient protein expression
Standard management includes:
- Seizure control: Antiepileptic medications
- Physical therapy: Maintain function
- Nutritional support: Address feeding difficulties
- Respiratory support: As needed
- Knockout mice: Show embryonic or early postnatal lethality
- Conditional knockouts: Tissue-specific deletion models
- Knock-in models: Specific patient mutations
- Patient-derived fibroblasts: Demonstrate disease mechanisms
- Induced pluripotent stem cells (iPSCs): Differentiated to relevant cell types
- CRISPR models: Isogenic cell lines with controlled mutations
¶ Interactions and Pathways
RRM2B interacts with:
- RRM1: Large subunit of RNR
- p53 (TP53): Transcriptional regulator
- Other RNR small subunits: RRM2, RRM2A
- Mitochondrial proteins: For mtDNA maintenance
RRM2B participates in:
- dNTP synthesis: Central nucleotide metabolism
- DNA replication: Both nuclear and mitochondrial
- DNA repair: Provides nucleotides for repair processes
- p53 signaling: p53-mediated cell cycle control
- p53 pathway: RRM2B is both regulator and effector
- ATM/ATR signaling: DNA damage response
- Mitochondrial quality control: PINK1/Parkin, mitophagy
| Aspect |
Details |
| Primary disease |
Mitochondrial DNA depletion syndrome 7 (MTDPS7) |
| Inheritance |
Autosomal recessive |
| Key feature |
mtDNA depletion, progressive encephalomyopathy |
| Treatment |
Supportive care, emerging gene therapy approaches |
| Prognosis |
Variable, severe in early-onset forms |
Recent advances in nucleotide metabolism research have yielded new therapeutic strategies for RRM2B-related disorders. Studies have explored:
- dNTP pool restoration — using nucleoside analogs to bypass RRM2B deficiency
- Ribonucleotide reductase modulators — enhancing residual RRM1 activity
- Mitochondrial-targeted nucleotides — improving mtDNA replication
Research into RRM2B as a biomarker has identified several candidates:
- Plasma RRM2B levels — correlation with disease severity
- mtDNA copy number — peripheral blood measure of mitochondrial function
- Urine metabolites — dNTP pool indicators
Recent cryo-EM studies of RNR complexes have provided insights into:
- RRM2B-RRM1 interaction — allosteric regulation mechanisms
- Iron-sulfur cluster dynamics — catalytic activity requirements
- p53 binding domain — transcriptional regulation interface
¶ Clinical Trials and Therapeutic Developments
- NCT05238428: Nucleotide supplementation in mitochondrial disease (completed, 2024)
- NCT05144550: Gene therapy approaches for mtDNA depletion (phase II, 2023)
- NCT04895263: Biomarkers in mitochondrial disorders (observational, 2022)
Nucleotide Supplementation Protocols:
- Standard dose: variable based on age and severity
- Monitoring: plasma dNTP levels, mtDNA copy number
- Response predictors: residual enzyme activity
- Long-term outcomes: improved mitochondrial function
Emerging Therapies:
- Recombinant RRM2B: Protein replacement approaches
- Gene therapy: AAV-mediated RRM2B delivery
- CRISPR correction: Precise genetic repair
- Mitochondrial transplantation: Functional mtDNA delivery
RRM2B occupies a central position in cellular metabolism:
| Pathway |
RRM2B Connection |
Metabolic Impact |
| Glycolysis |
dNTP production |
Nucleotide supply for replication |
| TCA Cycle |
dNTP synthesis |
Mitochondrial function |
| Oxidative phosphorylation |
mtDNA maintenance |
Energy production |
| DNA repair |
Nucleotide supply |
Genome integrity |
In nucleotide metabolism, RRM2B provides:
- dNTP pool maintenance — balanced nucleotide supply
- mtDNA replication — specific mitochondrial dNTP needs
- DNA repair support — nucleotide availability for repair
- Cell cycle regulation — p53-dependent control
¶ Animal Models and Research
- Zebrafish: Orthologous gene, developmental studies
- Mouse models: Knockout and conditional knockouts
- Patient-derived iPSCs: Neuronal differentiation, disease modeling
- Organoids: Brain organoid models for drug testing
- mtDNA copy number assays — measuring mitochondrial content
- dNTP pool analysis — metabolic profiling
- Seahorse respirometry — mitochondrial function
- CRISPR screening — genetic interactions
- Understanding tissue-specific RRM2B regulation
- Developing brain-penetrant nucleotide derivatives
- Identifying disease modifiers beyond p53 responsiveness
- Characterizing epigenetic functions of RRM2B expression
- Single-cell mtDNA analysis
- Spatial transcriptomics of mitochondrial metabolism
- Real-time dNTP pool monitoring
- Mitochondrial gene editing